Both cMet activation and EMT function as resistance mechanisms to EGFR tyrosine kinase inhibitors in NSCLC (Jakobsen et al, 2017; Ninomiya et al, 2018; Rotow & Bivona, 2017; Stewart et al, 2015; Yoshida et al, 2016). This evidence concerns the gene MET and non-small cell lung carcinoma.